IL143713A0 - Reverse hydroxamate inhibitors of matrix metalloproteinases - Google Patents
Reverse hydroxamate inhibitors of matrix metalloproteinasesInfo
- Publication number
- IL143713A0 IL143713A0 IL14371300A IL14371300A IL143713A0 IL 143713 A0 IL143713 A0 IL 143713A0 IL 14371300 A IL14371300 A IL 14371300A IL 14371300 A IL14371300 A IL 14371300A IL 143713 A0 IL143713 A0 IL 143713A0
- Authority
- IL
- Israel
- Prior art keywords
- matrix metalloproteinases
- hydroxamate inhibitors
- reverse hydroxamate
- reverse
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23908799A | 1999-01-27 | 1999-01-27 | |
| PCT/US2000/002038 WO2000044739A1 (en) | 1999-01-27 | 2000-01-27 | Reverse hydroxamate inhibitors of matrix metalloproteinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL143713A0 true IL143713A0 (en) | 2002-04-21 |
Family
ID=22900549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14371300A IL143713A0 (en) | 1999-01-27 | 2000-01-27 | Reverse hydroxamate inhibitors of matrix metalloproteinases |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20020007060A1 (cs) |
| EP (1) | EP1147101B1 (cs) |
| JP (1) | JP4718686B2 (cs) |
| KR (1) | KR100748010B1 (cs) |
| CN (1) | CN1222519C (cs) |
| AR (1) | AR029329A1 (cs) |
| AT (1) | ATE228122T1 (cs) |
| AU (1) | AU764383B2 (cs) |
| BG (1) | BG105782A (cs) |
| BR (1) | BR0007278A (cs) |
| CA (1) | CA2358951C (cs) |
| CO (1) | CO5150194A1 (cs) |
| CZ (1) | CZ20012591A3 (cs) |
| DE (1) | DE60000819T2 (cs) |
| DK (1) | DK1147101T3 (cs) |
| ES (1) | ES2187443T3 (cs) |
| HK (1) | HK1043115A1 (cs) |
| HU (1) | HUP0105477A2 (cs) |
| IL (1) | IL143713A0 (cs) |
| NO (1) | NO20013669L (cs) |
| NZ (1) | NZ512372A (cs) |
| PL (1) | PL349771A1 (cs) |
| PT (1) | PT1147101E (cs) |
| SK (1) | SK10582001A3 (cs) |
| TR (1) | TR200102159T2 (cs) |
| TW (1) | TWI225486B (cs) |
| WO (1) | WO2000044739A1 (cs) |
| ZA (1) | ZA200104979B (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| WO2003063762A2 (en) * | 2001-01-12 | 2003-08-07 | Abbott Laboratories | Process for the preparation of matrix metalloproteinase inhibitors |
| US7511144B2 (en) | 2001-09-07 | 2009-03-31 | Kaken Pharmaceutical Co., Ltd. | Reverse hydroxamic acid derivatives |
| EP2298733B1 (en) * | 2005-06-27 | 2016-05-25 | Nabriva Therapeutics AG | Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group |
| EP2543368A1 (en) | 2007-12-11 | 2013-01-09 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
| WO2015107139A1 (en) | 2014-01-17 | 2015-07-23 | Proyecto De Biomedicina Cima, S.L. | Compounds for use as antifibrinolytic agents |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2183905T3 (es) * | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
-
2000
- 2000-01-25 CO CO00003867A patent/CO5150194A1/es unknown
- 2000-01-26 AR ARP000100349A patent/AR029329A1/es not_active Application Discontinuation
- 2000-01-27 DE DE60000819T patent/DE60000819T2/de not_active Expired - Lifetime
- 2000-01-27 CN CNB008032378A patent/CN1222519C/zh not_active Expired - Fee Related
- 2000-01-27 WO PCT/US2000/002038 patent/WO2000044739A1/en not_active Application Discontinuation
- 2000-01-27 AU AU27391/00A patent/AU764383B2/en not_active Ceased
- 2000-01-27 JP JP2000595995A patent/JP4718686B2/ja not_active Expired - Fee Related
- 2000-01-27 SK SK1058-2001A patent/SK10582001A3/sk unknown
- 2000-01-27 PL PL00349771A patent/PL349771A1/xx not_active Application Discontinuation
- 2000-01-27 IL IL14371300A patent/IL143713A0/xx unknown
- 2000-01-27 CA CA002358951A patent/CA2358951C/en not_active Expired - Fee Related
- 2000-01-27 KR KR1020017009393A patent/KR100748010B1/ko not_active IP Right Cessation
- 2000-01-27 BR BR0007278-8A patent/BR0007278A/pt not_active Application Discontinuation
- 2000-01-27 TR TR2001/02159T patent/TR200102159T2/xx unknown
- 2000-01-27 PT PT00905758T patent/PT1147101E/pt unknown
- 2000-01-27 HU HU0105477A patent/HUP0105477A2/hu unknown
- 2000-01-27 NZ NZ512372A patent/NZ512372A/xx unknown
- 2000-01-27 ES ES00905758T patent/ES2187443T3/es not_active Expired - Lifetime
- 2000-01-27 AT AT00905758T patent/ATE228122T1/de not_active IP Right Cessation
- 2000-01-27 EP EP00905758A patent/EP1147101B1/en not_active Expired - Lifetime
- 2000-01-27 CZ CZ20012591A patent/CZ20012591A3/cs unknown
- 2000-01-27 DK DK00905758T patent/DK1147101T3/da active
- 2000-02-25 TW TW089101383A patent/TWI225486B/zh not_active IP Right Cessation
-
2001
- 2001-06-18 ZA ZA200104979A patent/ZA200104979B/en unknown
- 2001-07-16 US US09/905,242 patent/US20020007060A1/en not_active Abandoned
- 2001-07-26 NO NO20013669A patent/NO20013669L/no not_active Application Discontinuation
- 2001-08-03 BG BG105782A patent/BG105782A/xx unknown
-
2002
- 2002-04-18 HK HK02102947.8A patent/HK1043115A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL149118A0 (en) | Inhibitors of neuraminidases | |
| IL150712A0 (en) | Matrix metalloproteinase inhibitors | |
| EP1361873A4 (en) | Matrix metalloproteinase INHIBITORS | |
| HK1057746A1 (en) | Hydroxamate derivatives useful as deacetylase inhibitors | |
| HUP0200119A3 (en) | Sulfamato hydroxamic acid metalloprotease inhibitor | |
| PL343529A1 (en) | Substituted pyrrolidine hydroxamate metalloprotease inhibitors | |
| HK1045501A1 (zh) | 作為基質金屬蛋白酶抑制劑的異羥肟酸衍生物 | |
| AU2001265182A1 (en) | Inhibitors of matrix metalloproteinases | |
| HK1046289A1 (zh) | 凝血酶抑制劑的前體藥物 | |
| PL349771A1 (en) | Reverse hydroxamate inhibitors of matrix metalloproteinases | |
| AU2001241498A1 (en) | Matrix metalloproteinase inhibitors and uses thereof | |
| PL357084A1 (en) | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | |
| IL131047A0 (en) | Use of il-18 inhibitors | |
| AU2001274344A1 (en) | Tissue inhibitors of matrix metalloproteinases | |
| HUP0302904A3 (en) | Matrix metalloproteinase inhibitors | |
| SG119168A1 (en) | Utilization of at least one aminopeptidase inhibitor | |
| AU8005100A (en) | Inhibitors of neuraminidases | |
| SI1147101T1 (en) | Reverse hydroxamate inhibitors of matrix metalloproteinases | |
| GB9708133D0 (en) | Novel use of matrix metalloproteinase inhibitors | |
| IL145670A0 (en) | Prodrugs of thrombin inhibitors | |
| GB9822950D0 (en) | Therapeutic use of matrix metalloproteinase inhibitors | |
| GB9927780D0 (en) | The therapeutic use of matrix metalloproteinase inhibitors | |
| GB9818841D0 (en) | Pharmaceutical use of protease inhibitors | |
| IL147675A0 (en) | Use of il-18 inhibitors | |
| GB9627016D0 (en) | Novel use of matrix metalloproteinase inhibitors |